161 results on '"Martinelli, Giovanni"'
Search Results
2. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial
3. Geochemical characteristics of natural springs within the Lenglongling fault zone related to the Menyuan Ms 6.9 earthquake on January 8, 2022, NW China
4. Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study
5. Earthquake geochemical scientific expedition and research
6. Personalizing precision medicine: Patients with AML perceptions about treatment decisions
7. P-057 Role of the combination of FDG-PET plus whole body MRI for staging newly diagnosed and relapsed/refractory multiple myeloma: a prospective trial
8. MM-638 Role of the Combination of FDG-PET plus Whole Body MRI for Staging Newly Diagnosed and Relapsed/Refractory Multiple Myeloma (MM): A Prospective Trial
9. P-056 Role the combination of FDG pet plus whole body MRI for staging patients in high risk smoldering myeloma: a prospective trial
10. POSTER: MM-602 Role of the Combination of FDG-PET Plus Whole Body MRI for Staging Patients With High-Risk Smoldering Myeloma: A Prospective Trial
11. P-206 3D in vitro modelling of relapsed/refractory multiple myeloma to unveil mechanisms of acquired resistance to therapy
12. Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients
13. POSTER: MM-638 Role of the Combination of FDG-PET plus Whole Body MRI for Staging Newly Diagnosed and Relapsed/Refractory Multiple Myeloma (MM): A Prospective Trial
14. MM-602 Role of the Combination of FDG-PET Plus Whole Body MRI for Staging Patients With High-Risk Smoldering Myeloma: A Prospective Trial
15. Geochemical features and seismic imaging of the tectonic zone between the Tibetan Plateau and Ordos Block, central northern China
16. Generation of the 2022 Earthquake Swarm at Intersection of Four Geological Units at the Seismic Experimental Site, China
17. Effects of yoga practice on physiological distress, fatigue and QOL in patients affected by breast cancer undergoing adjuvant radiotherapy
18. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy
19. Poster: MM-494 Chemo or Chemo-Free Regimens in Heavily Pretreated Multiple Myeloma? Role of Bendamustine-Bortezomib-Dexamethasone (BVD) in Novel Agents' Era
20. Poster: MM-498 Addition of Carfilzomib as a Third Agent in Lenalidomide-Refractory Multiple Myeloma: Switching From Doublet to Triplet
21. AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions
22. Geochemical and geophysical effects of tectonic activity in faulted areas of the North China Craton
23. AML-389 Phase 1/2 Study of SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor, in Patients With IDH1/2-Mutated Acute Myeloid Leukemia: The DIAMOND-01 Trial
24. Poster: MDS-502 Supportive Care in Low-Risk Myelodysplastic Syndromes: Role of Erythropoiesis Stimulating Agents (ESAs)
25. MM-501 Domestic Opportunity in Heavily Pretreated Multiple Myeloma Not Eligible for Hospital-Based Treatment: Role of Pomalidomide-Dexamethasone
26. Poster: AML-389 Phase 1/2 Study of SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor, in Patients With IDH1/2-Mutated Acute Myeloid Leukemia: The DIAMOND-01 Trial
27. Poster: AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions
28. MM-499 Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment With Pomalidomide-Dexamethasone
29. Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations
30. P-236: Addition of carfilzomib as a third agent in lenalidomide-refractory multiple myeloma: switching from doublet to triplet
31. P-184: Pegfilgrastim versus filgrastim in the supportive care of heavily pretreated multiple myeloma in treatment with pomalidomide-dexamethasone
32. P-235: Chemo or chemo-free regimens in heavily pretreated multiple myeloma? Role of bendamustine-bortezomib-dexamethasone (BVD) in novel agents’ era
33. P-185: Domestic opportunity in heavily pretreated multiple myeloma not eligible to hospitalbased treatment: role of pomalidomide-dexamethasone
34. CometAnalyser: A user-friendly, open-source deep-learning microscopy tool for quantitative comet assay analysis
35. TARGETED THERAPY IN AML TREATMENT
36. Poster: ALL-132: Ponatinib Versus Imatinib with Reduced-Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): PhALLCON Study
37. CML-182: SETD2 Loss of Function Induces Genomic Instability in CML and May Contribute to Disease Progression to Blast Crisis
38. Poster: AML-347: A Preliminary Analysis of FLAM (Italian Non-Interventional Multi-Center Study of FLT3-Mutated AML Patients): FLT3 Receptor Gene Mutational Analysis and FLT3 Inhibitor Administration in Real-Life Clinical Practice
39. AML-091: Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib
40. ALL-132: Ponatinib Versus Imatinib with Reduced-Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia: (ALL): PhALLCON Study
41. MM-415: Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma
42. Poster: MM-409: Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pre-Treated Multiple Myeloma: Old/New in the Novel Agents’ Era
43. MM-418: Pegfilgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Pomalidomide-Based Treatment
44. AML-347: A Preliminary Analysis of FLAM (Italian Non-Interventional Multi-Center Study of FLT3-Mutated AML Patients): FLT3 Receptor Gene Mutational Analysis and FLT3 Inhibitor Administration in Real-Life Clinical Practice
45. Poster: CML-182: SETD2 Loss of Function Induces Genomic Instability in CML and May Contribute to Disease Progression to Blast Crisis
46. MM-409: Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pre-Treated Multiple Myeloma: Old/New in the Novel Agents’ Era
47. Poster: AML-091: Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib
48. Poster: MM-415: Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma
49. Poster: MM-418: Pegfilgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Pomalidomide-Based Treatment
50. Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome–positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.